What Lobe Sciences does

Lobe Sciences Ltd. is a Canadian public biopharmaceutical development company that advances therapeutic candidates for rare and underserved neurological and hematological conditions through focused subsidiary structures. Founded in 2018 and headquartered in Vancouver, British Columbia, the company trades on the Canadian Securities Exchange (CSE: LOBE), OTCQB (LOBEF), and Frankfurt Stock Exchange (FWB: LOBE), and employs 1-10 people directly. Its core assets are L-130 (Conjugated Psilocin / Psilocin Mucate), a proprietary conjugated psilocin compound covered by two U.S. patents valid until July 2043 and advanced through 64%-owned subsidiary Cynaptec Pharmaceuticals for chronic cluster headache, substance use disorders, and other CNS indications; S-100, a lipid-based therapeutic targeting red blood cell membrane dysfunction in sickle cell disease, advanced through subsidiary Applied Lipid Technologies; and Altemia, a market-ready medical food for sickle cell-related nutritional deficiencies.

The company's business model is asset-financing-driven rather than product-revenue-driven. Lobe is pre-revenue and does not maintain internal commercialization infrastructure; instead, it advances programs to defined clinical and regulatory milestones and partners with established pharmaceutical organizations for late-stage development and global commercialization, with anticipated revenue from licensing, co-development, or commercialization deals. The company funds operations through equity financings, private placements, and subsidiary-level rounds; in April 2025, Cynaptec secured US$6 million in subsidiary financing (with an option for an additional US$20 million) directed at Phase 3 trials and FDA NDA work for L-130.

Since an August 2024 management transition, Lobe has executed significant balance sheet restructuring: cash increased more than 24-fold to $5.99 million, liabilities fell 81% to $0.44 million, and net working capital improved to $6.1 million. R&D expenditures rose to $982,087 in Q1 2026 from $7,551 in the prior-year period as the L-130 program advanced. Operations are guided by a leadership team with prior experience at Johnson & Johnson, Pfizer, Gilead, aaiPharma/Alcami, and Ernst & Young, and a scientific advisory board drawn from Harvard, the University of Miami, and the World Headache Society.

Name

Lobe Sciences

Legal name

Lobe Sciences Ltd.

Website

https://lobesciences.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Lobe Sciences Ltd. is a Canadian public biopharmaceutical company that advances therapeutic candidates for chronic cluster headache, sickle cell disease, and substance use disorders through focused subsidiary companies. The company is pre-revenue and funds development via equity raises and subsidiary-level financing.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Pharmaceutical drug development
• Biopharmaceutical therapeutics
• Cluster headache treatment
• Sickle cell disease therapy
• Medical food products

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pre-revenue / Development Stage: Lobe Sciences is a pre-revenue biopharmaceutical company focused on advancing drug candidates through clinical development. The company does not generate product revenue and is financed through equity financings, private placements, subsidiary-level financing, and strategic partnerships. Revenue generation is anticipated through licensing, co-development, or commercialization partnerships with established pharmaceutical companies upon achievement of clinical milestones.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Lobe Sciences is a pre-revenue, clinical-stage biopharmaceutical company that develops drug candidates through focused subsidiaries, including L-130 (Conjugated Psilocin) for chronic cluster headache, S-100 lipid-based therapeutic for sickle cell disease, and the Altemia medical food for sickle cell disease nutritional support. The company plans to monetize its pipeline through licensing, co-development, or commercialization partnerships with established pharmaceutical companies after clinical milestones are achieved, rather than through internal sales infrastructure.

Product overview

Lobe Sciences Ltd. is a Canadian public biopharmaceutical company operating a pharmaceutical development platform through focused subsidiary companies. The company advances differentiated therapeutic assets targeting rare and underserved neurological and hematological conditions. The product portfolio includes three primary drug candidates: L-130 (Psilocin Mucate), a conjugated psilocin compound for chronic cluster headache developed through Cynaptec Pharmaceuticals (64%-owned subsidiary); S-100, a lipid-based therapeutic for sickle cell disease developed through Applied Lipid Technologies; and Altemia, a market-ready medical food for nutritional support in sickle cell disease. The development platform follows a structured five-step approach from asset identification through strategic partnerships for commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Conjugated Psilocin: Proprietary conjugated psilocin compound technology platform being advanced for pharmaceutical development
• Altemia
• S-100

Products and services

• L-130 (Psilocin Mucate) A proprietary conjugated psilocin compound designed for regulated pharmaceutical development and being advanced through subsidiary Cynaptec Pharmaceuticals for the treatment of chronic cluster headache and substance use disorders. Covered by two granted U.S. patents valid until July 2043.
• S-100 A lipid-based therapeutic candidate designed to address underlying cellular membrane dysfunction in sickle cell disease, aiming to improve red blood cell flexibility and reduce sickling events. Developed through subsidiary Applied Lipid Technologies.
• Altemia A medical food product providing nutritional support for deficiencies related to sickle cell disease. Listed as market-ready in the company pipeline. Dr. Herman Williams was appointed CEO of Altemia, Inc., and Dr. Harry R. Jacobson serves as Chairman of the Board of Altemia, Inc.
• Conjugated Psilocin (Platform Technology) A proprietary pharmaceutical platform technology being developed for multiple indications including chronic cluster headache, substance use disorders, and generalized anxiety disorder. Conjugated Psilocin is a registered trademark associated with the L-130 lead candidate.

Quantifiable outcome

• Cash increased more than 24-fold from $0.24M to $5.99M following strategic restructuring
• +4 more outcomes

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Massive Intelligence Pty LtdminorGTM or Marketing Partner · 21 April 2026Massive Intelligence, based in Melbourne, Australia, was engaged to provide investor relations and corporate communications services for an initial three-month term commencing April 15, 2026, at a cost of US $11,800 with option to renew for six months at US $31,500. Services include developing investor materials and corporate communications content distributed via social media, email, and press releases.
• Alera PharmacoreStrategic or Co-development Partner · 1 October 2024Alera Pharma collaborated with Lobe Sciences on the prosecution and issuance of two U.S. patents for Conjugated Psilocin (U.S. Patent 12,102,616 issued October 1, 2024, and a second patent issued November 11, 2024). The partnership covers patent prosecution for psilocin mucate compositions, methods of use, and production.

Scale indicators7 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• GH Research: Clinical-stage biopharma developing mebufotenin (5-MeO-DMT) for treatment-resistant depression. Comparable psychedelic-derived CNS therapy developer with a similar regulatory and clinical-execution playbook to Lobe.
• Cybin: Public psychedelic-based therapeutics company developing deuterated psilocybin analogs for CNS indications. Highly comparable to Lobe's approach of creating proprietary, stabilized psychedelic-derived molecules for regulatory development.
• Atai Life Sciences: Clinical-stage biopharma developing psychedelic-based therapies for mental health. Comparable to Lobe in psychedelic-derived CNS pipeline strategy and platform-of-subsidiaries operating model.
• MindMed: Clinical-stage psychedelic-inspired CNS biopharma developing psilocybin- and LSD-derived therapies. Comparable to Lobe in target indications (CNS, headache) and platform approach of stabilizing psychedelic molecules into pharmaceutical products.
• Tonix Pharmaceuticals: Public CNS biopharma with an active cluster headache program (TNX-1900, intranasal oxytocin). Direct competitor to Lobe in the same primary indication, chronic cluster headache.
• Global Blood Therapeutics: Acquired by Pfizer, developer of Oxbryta (voxelotor) for sickle cell disease. Direct peer for Lobe's sickle cell program (S-100/Applied Lipid Technologies) given same indication.
• Seelos Therapeutics: Small public CNS-focused biopharma with assets in depression, Parkinson's, and rare neurological conditions. Comparable to Lobe as a small-cap public CNS drug developer advancing niche neurological programs through capital-efficient structures.
• Compass Pathways: Public psychedelic therapy company developing a proprietary psilocybin formulation for treatment-resistant depression. Comparable as a psychedelic-derived CNS drug developer pursuing formal regulatory pathways, similar to Lobe's L-130.

Emerging players

• Emmaus Life Sciences: Small public biopharma commercializing Endari (L-glutamine) for sickle cell disease. Comparable as a small-cap company addressing sickle cell disease with a non-gene-therapy approach, similar to Lobe's S-100 and Altemia.
• BioXcel Therapeutics: Small public biopharma developing re-purposed and reformulated CNS drugs using a subsidiary-style platform approach. Comparable operating model (asset-focused, partnered commercialization) and similar CNS focus to Lobe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lobesciences
• Facebookfacebook.com/profile.php?id=61570412476630
• LinkedInlinkedin.com/company/lobe-sciences
• Instagraminstagram.com/lobesciences.ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lobe Sciences